Telix Pharmaceuticals was created to deliver on the promise of nuclear medicine
The field of nuclear medicine has historically lacked clinical momentum and commitment to late-stage product development. Our goal is to rectify this for the benefit of patients.
Launch of the International NOBLE Registry of Telix’s SPECT-Based Prostate Cancer Imaging Agent
Melbourne (Australia) and Brussels (Belgium) – 19 April 2021. Telix announces the launch of the international NOBLE Registry of Telix’s...
Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix®
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 31st March 2021. Telix announces it has completed an agreement with Grand River...
Telix Appoints Darren Patti, Chief Operating Officer, Telix Pharmaceuticals (US) Inc.
29th March 2021 – Corporate Spotlight | Darren Patti joins Telix as Chief Operating Officer, Telix Pharmaceuticals (US) Inc.
Telix Pharmaceuticals Limited – Notice of Annual General Meeting 2021
Melbourne (Australia) – 12 April 2021. Telix Pharmaceuticals provides notice of The Annual General Meeting of Shareholders on Wednesday 12...